Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data

The Journal of Biological Chemistry
Mack R KuoDavid A Fidock

Abstract

Tuberculosis and malaria together result in an estimated 5 million deaths annually. The spread of multidrug resistance in the most pathogenic causative agents, Mycobacterium tuberculosis and Plasmodium falciparum, underscores the need to identify active compounds with novel inhibitory properties. Although genetically unrelated, both organisms use a type II fatty-acid synthase system. Enoyl acyl carrier protein reductase (ENR), a key type II enzyme, has been repeatedly validated as an effective antimicrobial target. Using high throughput inhibitor screens with a combinatorial library, we have identified two novel classes of compounds with activity against the M. tuberculosis and P. falciparum enzyme (referred to as InhA and PfENR, respectively). The crystal structure of InhA complexed with NAD+ and one of the inhibitors was determined to elucidate the mode of binding. Structural analysis of InhA with the broad spectrum antimicrobial triclosan revealed a unique stoichiometry where the enzyme contained either a single triclosan molecule, in a configuration typical of other bacterial ENR:triclosan structures, or harbored two triclosan molecules bound to the active site. Significantly, these compounds do not require activation and a...Continue Reading

References

Dec 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·D S PetersonT E Wellems
Sep 30, 1983·Biochemical and Biophysical Research Communications·T HayashiH Okazaki
Aug 1, 1984·Journal of Medicinal Chemistry·M A GrassbergerJ Hildebrandt
Jul 23, 1996·Proceedings of the National Academy of Sciences of the United States of America·J D Palmer, C F Delwiche
Dec 6, 1997·Nature·M E Fichera, D S Roos
Dec 12, 1997·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·G I McFadden, R F Waller
Oct 3, 1998·Acta Crystallographica. Section D, Biological Crystallography·A T BrüngerG L Warren
Oct 15, 1998·Proceedings of the National Academy of Sciences of the United States of America·R F WallerG I McFadden
Nov 7, 1998·The Journal of Biological Chemistry·R J HeathC O Rock
Apr 10, 1999·The Journal of Biological Chemistry·R J HeathC O Rock
Apr 14, 1999·Nature·C W LevyJ B Rafferty
Jul 10, 1999·Journal of Molecular Biology·M J StewartC Kisker
Oct 16, 1999·The Journal of Biological Chemistry·A RoujeinikovaD W Rice
Dec 14, 1999·Protein Science : a Publication of the Protein Society·X QiuS S Abdel-Meguid
Dec 28, 1999·Journal of Molecular Biology·A RoujeinikovaD W Rice
Jan 25, 2000·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·P EscalanteJ M Musser
Jul 12, 2002·Journal of Medicinal Chemistry·William H MillerWilliam F Huffman
Sep 18, 2002·Antimicrobial Agents and Chemotherapy·David J PayneWilliam F Huffman
Jan 1, 1997·Methods in Enzymology·Zbyszek Otwinowski, Wladek Minor

❮ Previous
Next ❯

Citations

Sep 26, 2009·Journal of Molecular Modeling·Ashutosh Kumar, Mohammad Imran Siddiqi
Nov 15, 2011·Journal of Computer-aided Molecular Design·Benjamin SchaeferChristoph A Sotriffer
Dec 17, 2003·Current Opinion in Structural Biology·Clare V Smith, James C Sacchettini
Aug 9, 2003·International Journal for Parasitology·Piotr Gornicki
Jan 16, 2008·Accounts of Chemical Research·Hao Lu, Peter J Tonge
Feb 5, 2011·Journal of Chemical Information and Modeling·Sarah L KinningsPhilip E Bourne
Jul 31, 2013·Journal of Chemical Information and Modeling·Ivani PauliOsmar Norberto de Souza
Oct 27, 2011·Chemical Reviews·Cyrille Y BottéChristophe Biot
Oct 25, 2012·The Journal of Antibiotics·Lissinda H Du PlessisAwie F Kotzé
Jun 3, 2004·Nature Reviews. Drug Discovery·David A FidockSolomon Nwaka
Nov 3, 2006·Nature Reviews. Drug Discovery·Solomon Nwaka, Alan Hudson
Dec 15, 2007·Nature Reviews. Microbiology·James C SacchettiniJoel S Freundlich
Sep 8, 2009·The Journal of Antimicrobial Chemotherapy·Kathleen EnglandRichard A Slayden
Jul 13, 2011·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Eric H EklandDavid A Fidock
Oct 3, 2012·Acta Crystallographica. Section F, Structural Biology and Crystallization Communications·José M OteroMark J van Raaij
Jun 2, 2011·Antimicrobial Agents and Chemotherapy·Catherine VilchèzeWilliam R Jacobs
May 27, 2005·Antimicrobial Agents and Chemotherapy·Lluis BallellRobert J Young
Nov 23, 2012·BMC Bioinformatics·Rodrigo C BarrosOsmar Norberto de Souza
Jan 20, 2011·BMC Genomics·Karina S MachadoOsmar Norberto de Souza
Feb 26, 2014·BMC Genomics·Ana T WinckDuncan D Ruiz
Nov 17, 2010·PLoS Computational Biology·Sarah L KinningsPhilip E Bourne
Jun 29, 2011·Future Microbiology·Claudia Sala, Ruben C Hartkoorn
Dec 3, 2013·Nature Chemical Biology·Ruben C HartkoornStewart T Cole
Jun 2, 2012·Expert Opinion on Drug Discovery·Christopher H Miller, Ronan F O'Toole
Jul 19, 2005·Expert Opinion on Investigational Drugs·Dharmendar RathoreSanjai Kumar
Nov 11, 2014·Journal of Enzyme Inhibition and Medicinal Chemistry·Ondrej HolasMartin Dolezal
Jan 22, 2013·Pulmonary Pharmacology & Therapeutics·Parveen KumarSarman Singh
Feb 25, 2005·Biological Reviews of the Cambridge Philosophical Society·R J M Iain Wilson

❮ Previous
Next ❯

Related Concepts

Related Feeds

ASBMB Publications

The American Society for Biochemistry and Molecular Biology (ASBMB) includes the Journal of Biological Chemistry, Molecular & Cellular Proteomics, and the Journal of Lipid Research. Discover the latest research from ASBMB here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.